Related Experiment Video
Updated: May 1, 2026
06:24
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
1.9K
Lymphocytic colitis associated with lansoprazole treatment
Zahide Simsek1, Hakan Alagozlu2, Candan Tuncer2
1Department of Gastroenterology, Faculty of Medicine, Gazi University Hospital, Ankara, Turkey ; Department of Pathology, Faculty of Medicine, Gazi University Hospital, Ankara, Turkey.
Current Therapeutic Research, Clinical and Experimental
|April 3, 2014
Summary
Proton pump inhibitors like lansoprazole may cause lymphocytic colitis (LC), a rare inflammatory bowel disease. Discontinuing lansoprazole led to symptom resolution in two patients, suggesting a probable link.
Area of Science:
- Gastroenterology
- Pharmacology
- Internal Medicine
Background:
- Lymphocytic colitis (LC) and collagenous colitis (CC) are distinct inflammatory bowel diseases.
- Few cases of lansoprazole-associated LC have been reported, contrasting with more frequent CC associations.
- Proton pump inhibitors (PPIs) are widely used for gastroesophageal reflux disease (GERD) and Helicobacter pylori eradication.
Purpose of the Study:
- To report two cases of lymphocytic colitis (LC) potentially associated with lansoprazole use.
- To highlight the possibility of lansoprazole-induced LC in patients presenting with chronic diarrhea.
- To evaluate the causality between lansoprazole and LC using the Naranjo scale.
Main Methods:
- Case report detailing two patients with chronic diarrhea and abdominal pain.
- Diagnostic confirmation of LC through colon biopsies.
- Literature review of lansoprazole-associated colitis.
- Causality assessment using the Naranjo adverse reaction algorithm.
Main Results:
- Two patients diagnosed with LC after lansoprazole exposure.
- Patient 1 experienced complete symptom resolution within 7 days of lansoprazole discontinuation.
- Patient 2 showed symptom improvement after switching from lansoprazole to omeprazole.
- Naranjo scale scores of 6 for both patients indicated probable association between lansoprazole and LC.
Conclusions:
- Lansoprazole treatment is probably associated with the development of lymphocytic colitis (LC).
- Discontinuation of lansoprazole can lead to complete remission of LC symptoms.
- Clinicians should consider lansoprazole as a potential cause in patients diagnosed with LC.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
1.4K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.4K
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
33
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
33
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.3K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K